> very had to predict what binds to what, which of course is a multi-billion-dollar industry.

Do you need to predict when AP-MS is so cheap?

Mapping interaction interfaces is challenging and is where there is attention. I don’t think we’re going to get complexes as a commercial focus outside of receptors with known quaternary structure. The first issue, as you allude to, is the absence of training data, which itself highlights the relative commercial unimportance of such an endeavor.

> None of them can predict anything complex or 'big', everything is peptide-level.

Is this related to the current peptide boom?